Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 73-90 , March 2003

Hormone replacement therapy, cardiovascular and cerebrovascular disease

  • Helena J Teede, MBBS, FRACP, PhD (Senior Lecturer)

      Affiliations

    • Corresponding Author InformationTel.: +61-3-9554-8024; Fax: +61-3-9554-8027.

Received 1 August 2002 ,Accepted 1 September 2002.

References 

  1. Stampfer MJ, Hu FB, Manson JE, et al.  Primary prevention of coronary heart disease in women through diet and lifestyle. New England Journal of Medicine. 2000;343:16–22
  2. In:  Yusef S, et al. editor. Evidence-Based Cardiology. London: BMJ Books; 1998;
  3. Teede HJ, McGrath BP. Cardiovascular effects of sex hormones. Clinical Science. 1999;97:1–3
  4. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association. 1998;280:605–613
  5. Writing Group for the Women's Health Initiative . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association. 2002;288:321–333
  6. Mosca L, Herrington DM, Mendelsohn ME, et al.  Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503
  7. Mosa L, Grundy SM, Judeksin D, et al.  Guide to preventive cardiology for women. Circulation. 1999;99:2480–2484
  8. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997. Medical Journal of Australia. 1999;170:524–527
  9. Grady D, Rubin SM, Petitti DB, et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine. 1992;117:1016–1037
  10. Teede HJ. Hormone replacement therapy and the prevention of cardiovascular disease. Human Reproduction Update. 2002;8:201–215
  11. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Progress in Cardiovascular Disease. 1995;38:199–210
  12. Alexander KP, Newby LK, Hellkamp AS, et al.  Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. Journal of the American College of Cardiology. 2001;38:1–7
  13. Simon JA, Hsia J, Cauely JA, et al.  Postmenopausal hormone replacement therapy and risk of stroke. Circulation. 2001;103:638–642
  14. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Annals of Internal Medicine. 1991;115:455–456
  15. Grodstein F, Stampfer MJ, Manson JE, et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine. 1996;335:453–461
  16. Sitruk-Ware R. Progestins and the cardiovascular system. In:  Genazzani AR editors. Hormone Replacement Therapy and Cardiovascular Disease. New York: Parthenon; 2001;p. 37–43
  17. Anonymous . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. Journal of the American Medical Association. 1995;273:199–208
  18. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertility & Sterility. 2001;75:898–915
  19. Teede HJ, Liang Y-L, Zoungas S, et al.  A placebo controlled trial of transdermal estrogen replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Climacteric. 2001;4:1–10
  20. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680–1687
  21. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. American Journal of Physiology. 1997;272:H2765–H2773
  22. Hishikawa , Nakaki T, Marumo T, et al.  Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Letters. 1995;360:291–293
  23. van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Current Medical Chemistry. 2000;7:499–517
  24. Teede HJ, Liang Y, Kotsopoulos D, et al.  A placebo controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clinical Endocrinology. 2001;55:673–682
  25. Sanderson JE, Haines CJ, Yeung L, et al.  Anti-ischemic action of estrogen–progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: a randomized, placebo-controlled, double-blind parallel group trial. Journal of Cardiovascular Pharmacology. 2001;38:372–383
  26. Rosano GMC, Caixeta AM, Chierchia SL, et al.  Acute anti-ischemic effect of estradiol in postmenopausal women with coronary artery disease. Circulation. 1999;96:2837–2841
  27. Alkayed NJ, Murphy SJ, Traystman RJ, et al.  Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke. 2000;31:161–168
  28. Clarkson TB, Hughes CL, Klein KP. The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Progress in Cardiovascular Disease. 1995;38:189–198
  29. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. Journal of Clinical Endocrinology and Metabolism. 2001;86:5396–5404
  30. Wagner JD, Cefalu WT, Anthony MS, et al.  Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 1997;46:698–705
  31. Brehme U, Bruck B, Gugel N, et al.  Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous sequential progestin. Arteriosclerosis, Thrombosis and Vascular Biology. 1999;19:1930–1937
  32. Adams MR, Kaplan JR, Manuck SB, et al.  Inhibition of coronary artery atherosclerosis by 17-b estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051–1057
  33. White CR, Shelton J, Chen SJ, et al.  Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation. 1997;96:1624–1630
  34. Makela S, Savolainen H, Aavik E, et al.  Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proceedings of the National Academy of Sciences of the USA. 1999;96:7077–7082
  35. Oparil S, Levine RL, Chen SJ, et al.  Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1999;95:1301–1307
  36. Theroux P, Cairns JA. Unstable angina. In:  Yusef S, et al. editor. Evidence Based Cardiology. London: BMJ Books; 1998;p. 395–417
  37. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  38. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischaemic death. New England Journal of Medicine. 1984;310:1137–1140
  39. Coronary Drug Project Research Group . The Coronary Drug Projects initial findings leading to modifications of the research protocol. Journal of the American Medical Association. 1970;214:308–313
  40. Hoibraaten E, Qvigstad E, Arnesen H, et al.  Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thrombosis and Haemostasis. 2000;84:961–967
  41. Teede HJ, McGrath BP, Smolich JJ, et al.  Postmenopausal hormone replacement therapy increases both coagulation activity and fibrinolysis. Arteriosclerosis Thrombosis and Vascular Biology. 2000;20:1404–1409
  42. Hoibraaten E, Qvigstad E, Andersen TO, et al.  The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism—results from a rendomised, double-blind, clinical trial. Thrombosis and Haemostasis. 2001;85:775–781
  43. Teede HJ, Majewski H, McGrath BP, Turner A. Platelet aggregation is not reduced in postmenopausal women on oral hormone replacement therapy. Clinical Science. 2001;100:207–213
  44. Grady D, Wenger NK, Herrington D, et al.  Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study. Annals of Internal Medicine. 2000;132:689–696
  45. Psaty BM, Smith NL, Lamaitre RN, et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infraction in postmenopausal women. Journal of the American Medical Association. 2001;285:906–916
  46. Koenig W. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?. Italian Heart Journal. 2001;2:157–163
  47. Walsh BW, Paul S, Wild RA, et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomised controlled trial. Journal of Clinical Endocrinology and Metabolism. 2000;85:214–218
  48. Mosca L. Hormone replacement therapy and myocardial infarction. In:  Genazzani AR editors. Hormone Replacement Therapy and Cardiovascular Disease. New York: Parthenon; 2001;p. 173–176
  49. Grady D, Herrington D, Bittner V, et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). Journal of the American Medical Association. 2002;288:49–57
  50. Herrington DM, Reboussiin DM, Brosnihan KB, et al.  Effects of estrogen replacement therapy on the progression of coronary artery atherosclerosis. New England Journal of Medicine. 2000;343:522–529
  51. Viscoli CM, Brass LM, Kernan WN. A clinical trial of estrogen-replacement therapy after ischaemic stroke. New England Journal of Medicine. 2001;345:1243–1249
  52. Angerer P, Stork S, Kothny W, et al.  Effects of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomised controlled trial. Arteriosclerosis, Thrombosis and Vascular Biology. 2001;21:262–268
  53. Hodis HN, Mack WJ, Lobo RA, et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2001;135:939–953
  54. Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of post menopausal HRT on cardiovascular disease. Lancet. 2000;355:566–569
  55. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annual Review of Public Health. 1998;19:55–72
  56. Anderson F. Kinetics and pharmacology of estrogens in pre- and postmenopausal women. International Journal of Fertility. 2000;38:55–64
  57. Whitehead M. Progestins and androgens. Fertility and Sterility. 1994;62:161–167
  58. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Journal of the North American Menopause Society. 1999;6:273–276
  59. Utian WH, Shoupe D, Bachmann G, et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility. 2001;75:1065–1079
  60. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors and carbohydrate metabolism. Fertility and Sterility. 2001;76:13–24
  61. Crook D. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial). In:  Genazzani AR editors. Hormone Replacement Therapy and Cardiovascular Disease. New York: Parthenon; 2001;p. 165–172
  62. Hammer M, Christau S, Nathorst-Boos J, et al.  A double blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. British Journal of Obstetrics and Gynaecology. 1998;105:904–911
  63. Zandberg P, Peters JL, Demacker PN, et al.  Tibolone prevents atherosclerotic lesion formation in cholesterol fed ovariectomised rabbits. Arteriosclerosis, Thrombosis and Vascular Biology. 1998;8:1844–1854
  64. Winkler UH, Altkemper R, Kwee B, et al.  Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomised study. Fertility and Sterility. 2000;74:10–19
  65. Bush TL, Blumenthal R, Lobo R, Clarkson TB. SERMs and cardiovascular disease in women. How do these agents affect risk?. Postgraduate Medicine. 2001;(Spec. No.):17–24
  66. Moscarelli E, Cox DA. Cardiovascular effects of raloxifene: data from preclinical studies and clinical trials in postmenopausal women. In:  Genazzani AR editors. Hormone Replacement Therapy and Cardiovascular Disease. New York: Parthenon; 2000;p. 159–164
  67. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. Journal of Clinical Endocrinology and Metabolism. 1998;83:721–726
  68. Reis SE, Costantino JP, Wickerham DL, et al.  Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. Journal of the National Cancer Institute. 2001;93:16–21
  69. Barrett-Connor E, Grady D, Sashegyi A, et al.  Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Journal of the American Medical Association. 2002;287:847–857
  70. Ades P. Cardiac rehabilitation and secondary prevention of coronary heart disease. New England Journal of Medicine. 2001;345:892–902
  71. Mosca L, Jones WJ, King KB, et al.  Awareness, perception and knowledge of heart disease risk and prevention among women in the Unites States. Archives of Family Medicine. 2000;9:506–515

PII: S1521-690X(02)00083-0

doi: 10.1016/S1521-690X(02)00083-0

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 73-90 , March 2003

Article Tools

* Image Usage & Resolution